PARP1 and ovarian carcinoma: PARP inhibitors, such as olaparib, niraparib, rucaparib, veliparib, and fuzuloparib, have shown encouraging results in the treatment of epithelial ovarian cancer (high-grade serous or endometrioid adenocarcinoma) in phase III clinical trials in recent years [4,5,6,7,8,9,10].